Literature DB >> 14697462

Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.

Ernst J Schaefer1, Judith R McNamara, Timothy Tayler, Jennifer A Daly, Joi L Gleason, Leo J Seman, Andrea Ferrari, Joel J Rubenstein.   

Abstract

The effects of atorvastatin at 20, 40, and 80 mg/day on plasma lipoprotein subspecies were examined in a randomized, placebo-controlled fashion over 36 weeks in 97 patients with coronary heart disease (CHD) with low-density lipoprotein (LDL) cholesterol levels of >130 mg/dl and compared directly with the effects of fluvastatin (n = 28), pravastatin (n = 22), lovastatin (n = 24), and simvastatin (n = 25). The effects of placebo and 40 mg/day of each statin were also examined in subjects with CHD with subjects in the fasting state and in the fed state 4 hours after a meal rich in saturated fat and cholesterol and compared with results in age- and gender-matched control subjects. At all doses tested in the fasting and fed states, atorvastatin was significantly (p <0.01) more effective in lowering LDL cholesterol and non-high-density lipoprotein (HDL) cholesterol than all other statins, and significantly (p <0.05) more effective than all statins, except for simvastatin, in lowering triglyceride and remnant lipoprotein (RLP) cholesterol. At 40 mg/day in the fasting state, atorvastatin was significantly (p <0.01) more effective than all statins, except for lovastatin and simvastatin, in lowering cholesterol levels in small LDL, and was significantly (p <0.05) more effective than all statins, except for simvastatin, in increasing cholesterol in large HDL and in lowering LDL particle numbers. Our data indicate that atorvastatin was the most effective statin tested in lowering cholesterol in LDL, non-HDL, and RLP in the fasting and fed states, and getting patients with CHD to established goals, with fluvastatin, pravastatin, lovastatin, and simvastatin having about 33%, 50%, 60%, and 85% of the efficacy of atorvastatin, respectively, at the same dose in the same patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14697462     DOI: 10.1016/j.amjcard.2003.09.008

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  29 in total

1.  Influence of simvastatin on apoB-100 secretion in non-obese subjects with mild hypercholesterolemia.

Authors:  Heiner K Berthold; Jessica Mertens; Julia Birnbaum; Susanne Brämswig; Thomas Sudhop; P Hugh R Barrett; Klaus von Bergmann; Ioanna Gouni-Berthold
Journal:  Lipids       Date:  2010-05-12       Impact factor: 1.880

Review 2.  Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials.

Authors:  Amirhossein Sahebkar; Luis E Simental-Mendía; Claudio Pedone; Gianna Ferretti; Petr Nachtigal; Simona Bo; Giuseppe Derosa; Pamela Maffioli; Gerald F Watts
Journal:  Br J Clin Pharmacol       Date:  2016-02-02       Impact factor: 4.335

3.  Importance of the lipid-related pathways in the association between statins, mortality, and cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Denis Talbot; Joseph A Chris Delaney; Veit Sandfort; David M Herrington; Robyn L McClelland
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-02-06       Impact factor: 2.890

4.  Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency.

Authors:  David A Sheridan; S H Bridge; M M E Crossey; D J Felmlee; H C Thomas; R D G Neely; S D Taylor-Robinson; M F Bassendine
Journal:  Metab Brain Dis       Date:  2014-03-12       Impact factor: 3.584

Review 5.  The effects of statins on high-density lipoproteins.

Authors:  Ernst J Schaefer; Bela F Asztalos
Journal:  Curr Atheroscler Rep       Date:  2006-01       Impact factor: 5.113

6.  Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.

Authors:  Vasilios G Athyros; Anna I Kakafika; Athanasios A Papageorgiou; Konstantinos Tziomalos; Athanasios Skaperdas; Efstathios Pagourelias; Athina Pirpasopoulou; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Lipids       Date:  2007-08-23       Impact factor: 1.880

7.  Genome-wide linkage scan for plasma high density lipoprotein cholesterol, apolipoprotein A-1 and triglyceride variation among American Indian populations: the Strong Heart Family Study.

Authors:  X Li; K L Monda; H H H Göring; K Haack; S A Cole; V P Diego; L Almasy; S Laston; B V Howard; N M Shara; E T Lee; L G Best; R R Fabsitz; J W MacCluer; Kari E North
Journal:  J Med Genet       Date:  2009-05-07       Impact factor: 6.318

8.  Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels.

Authors:  Seiko Otokozawa; Masumi Ai; Thomas Van Himbergen; Bela F Asztalos; Akira Tanaka; Evan A Stein; Peter H Jones; Ernst J Schaefer
Journal:  Atherosclerosis       Date:  2008-11-12       Impact factor: 5.162

9.  Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein.

Authors:  S Lally; C Y Tan; D Owens; G H Tomkin
Journal:  Diabetologia       Date:  2006-03-04       Impact factor: 10.122

10.  Effects of statin treatment with atorvastatin on urolithiasis-associated urinary metabolic risk factors: an experimental study.

Authors:  Mustafa Zafer Temiz; Emrah Yuruk; Kasim Ertas; Oguzhan Zengi; Atilla Semercioz
Journal:  Int Urol Nephrol       Date:  2017-12-02       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.